Who Generates Higher Gross Profit? Biogen Inc. or Bausch Health Companies Inc.

Biogen's Gross Profit Dominance Over Bausch Health: A Decade in Review

__timestampBausch Health Companies Inc.Biogen Inc.
Wednesday, January 1, 201460089000008532288000
Thursday, January 1, 201578538000009523400000
Friday, January 1, 201670630000009970100000
Sunday, January 1, 2017617600000010643900000
Monday, January 1, 2018602900000011636600000
Tuesday, January 1, 2019625100000012422500000
Wednesday, January 1, 2020577800000011639400000
Friday, January 1, 202160400000008872000000
Saturday, January 1, 202257600000007895100000
Sunday, January 1, 202361980000007302200000
Monday, January 1, 20249675900000
Loading chart...

Data in motion

Biogen Inc. vs. Bausch Health Companies Inc.: A Decade of Gross Profit Analysis

In the competitive landscape of the pharmaceutical industry, understanding which companies lead in profitability is crucial. Over the past decade, Biogen Inc. has consistently outperformed Bausch Health Companies Inc. in terms of gross profit. From 2014 to 2023, Biogen's average gross profit was approximately 55% higher than that of Bausch Health. Notably, Biogen peaked in 2019 with a gross profit of around $12.4 billion, while Bausch Health's highest was in 2015, reaching nearly $7.9 billion. Despite fluctuations, Biogen maintained a strong lead, particularly between 2017 and 2020, where its profits were over 70% higher than Bausch Health's. This trend highlights Biogen's robust market position and strategic financial management. As the industry evolves, these insights provide a valuable perspective on the financial health and competitive dynamics of these pharmaceutical giants.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025